Core Viewpoint - Xuan Bamboo Biotech-B (02575) shares rose nearly 3%, currently up 1.98% at HKD 66.95, with a trading volume of HKD 15.1953 million following the announcement of its innovative drug, Pirlosil, being included in the 2025 National Basic Medical Insurance Directory [1] Group 1 - The innovative drug Pirlosil (brand name: Xuan Yue Ning) has been included in the 2025 National Basic Medical Insurance Directory, which will be implemented on January 1, 2026 [1] - The inclusion in the insurance directory is expected to enhance the affordability and accessibility of Xuan Yue Ning for patients, thereby promoting market expansion and increasing sales scale [1] - The company plans to actively support the implementation of the insurance policy, continue to advance hospital access, expand core markets, and increase market coverage to improve patient access to medication [1]
轩竹生物-B涨近3% 自研创新药轩悦宁 首次纳入2025国家基本医保目录